These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 2160032)

  • 1. Topoisomerases, new targets in cancer chemotherapy.
    Zijlstra JG; de Jong S; de Vries EG; Mulder NH
    Med Oncol Tumor Pharmacother; 1990; 7(1):11-8. PubMed ID: 2160032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topoisomerase enzymes as drug targets.
    Guichard SM; Danks MK
    Curr Opin Oncol; 1999 Nov; 11(6):482-9. PubMed ID: 10550012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
    Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
    Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs.
    D'Arpa P
    Adv Pharmacol; 1994; 29B():127-43. PubMed ID: 8996605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [DNA topoisomerase inhibitor].
    Hino M; Niitani H
    Nihon Rinsho; 1993 Dec; 51(12):3291-300. PubMed ID: 8283648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
    Tse-Dinh YC
    Infect Disord Drug Targets; 2007 Mar; 7(1):3-9. PubMed ID: 17346206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT; Danks MK
    Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
    Thielmann HW; Popanda O; Gersbach H; Gilberg F
    Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
    Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs acting on DNA topoisomerases: recent advances and future perspectives.
    Gatto B; Capranico G; Palumbo M
    Curr Pharm Des; 1999 Mar; 5(3):195-215. PubMed ID: 10066890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of resistance to topoisomerases poisons.
    Prost S
    Gen Pharmacol; 1995 Dec; 26(8):1773-84. PubMed ID: 8745168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
    Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
    Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
    Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
    Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
    Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
    Sinha BK
    Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA topoisomerases as targets for anticancer drugs.
    Topcu Z
    J Clin Pharm Ther; 2001 Dec; 26(6):405-16. PubMed ID: 11722677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yeast systems for demonstrating the targets of anti-topoisomerase II agents.
    Nitiss JL; Nitiss KC
    Methods Mol Biol; 2001; 95():315-27. PubMed ID: 11089243
    [No Abstract]   [Full Text] [Related]  

  • 19. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
    Padget K; Stewart A; Charlton P; Tilby MJ; Austin CA
    Biochem Pharmacol; 2000 Sep; 60(6):817-21. PubMed ID: 10930536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AK37: the first pyridoacridine described capable of stabilizing the topoisomerase I cleavable complex.
    Marshall KM; Holden JA; Koller A; Kashman Y; Copp BR; Barrows LR
    Anticancer Drugs; 2004 Oct; 15(9):907-13. PubMed ID: 15457132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.